Literature DB >> 22195963

Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.

David Matallanas1, David Romano, Fahd Al-Mulla, Eric O'Neill, Waleed Al-Ali, Piero Crespo, Brendan Doyle, Colin Nixon, Owen Sansom, Matthias Drosten, Mariano Barbacid, Walter Kolch.   

Abstract

K-Ras mutations are frequent in colorectal cancer (CRC), albeit K-Ras is the only Ras isoform that can elicit apoptosis. Here, we show that mutant K-Ras directly binds to the tumor suppressor RASSF1A to activate the apoptotic MST2-LATS1 pathway. In this pathway LATS1 binds to and sequesters the ubiquitin ligase Mdm2 causing stabilization of the tumor suppressor p53 and apoptosis. However, mutant Ras also stimulates autocrine activation of the EGF receptor (EGFR) which counteracts mutant K-Ras-induced apoptosis. Interestingly, this protection requires the wild-type K-Ras allele, which inhibits the MST2 pathway in part via AKT activation. Confirming the pathophysiological relevance of the molecular findings, we find a negative correlation between K-Ras mutation and MST2 expression in human CRC patients and CRC mouse models. The small number of tumors with co-expression of mutant K-Ras and MST2 has elevated apoptosis rates. Thus, in CRC, mutant K-Ras transformation is supported by the wild-type allele.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22195963     DOI: 10.1016/j.molcel.2011.10.016

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  75 in total

1.  The RASSF1A tumor suppressor regulates XPA-mediated DNA repair.

Authors:  Howard Donninger; Jennifer Clark; Francesca Rinaldo; Nicholas Nelson; Thibaut Barnoud; M Lee Schmidt; Katharine R Hobbing; Michele D Vos; Brian Sils; Geoffrey J Clark
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

2.  RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis.

Authors:  M Lee Schmidt; Katharine R Hobbing; Howard Donninger; Geoffrey J Clark
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

3.  The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation.

Authors:  Ning Yin; Adrienne Lepp; Yongsheng Ji; Matthew Mortensen; Songwang Hou; Xiao-Mei Qi; Charles R Myers; Guan Chen
Journal:  J Biol Chem       Date:  2017-07-24       Impact factor: 5.157

4.  Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.

Authors:  Ana Sebio; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

5.  Wild-type RAS: keeping mutant RAS in CHK.

Authors:  Theonie Anastassiadis; Eric J Brown
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

6.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Authors:  Elda Grabocka; Yuliya Pylayeva-Gupta; Mathew J K Jones; Veronica Lubkov; Eyoel Yemanaberhan; Laura Taylor; Hao Hsuan Jeng; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

Review 7.  The Mystery of Rap1 Suppression of Oncogenic Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Mingzhen Zhang; Chung-Jung Tsai; Anna A Sablina
Journal:  Trends Cancer       Date:  2020-03-02

8.  The differential effects of wild-type and mutated K-Ras on MST2 signaling are determined by K-Ras activation kinetics.

Authors:  David Romano; Helene Maccario; Carolanne Doherty; Niall P Quinn; Walter Kolch; David Matallanas
Journal:  Mol Cell Biol       Date:  2013-03-04       Impact factor: 4.272

Review 9.  Hras helps hippo heterodimerize to evade tumor suppression.

Authors:  Daniela Araiza-Olivera; Jonathan Chernoff
Journal:  Small GTPases       Date:  2016-09-20

Review 10.  The dynamic control of signal transduction networks in cancer cells.

Authors:  Walter Kolch; Melinda Halasz; Marina Granovskaya; Boris N Kholodenko
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.